Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Kavanaugh

Showing results (101-110 of 381) with videos related to

Pageof 39
Sort By:
The Journal of Rheumatology|October 15, 2022
Prologue: Evidence Informing the GRAPPA 2021 Treatment Recommendations, by DomainEnrique R Soriano, Arthur Kavanaugh, Laura C Coates
The Journal of Rheumatology|February 16, 2022
Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic ArthritisDeepak R Jadon, Arthur Kavanaugh, Ying Ying Leung
Current Opinion in Rheumatology|February 8, 2006
Recent developments in diet and goutSusan J Lee, Robert A Terkeltaub, Arthur Kavanaugh
Gastroenterology|August 6, 2021
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease ManagementGerhard Rogler, Abha Singh, Arthur Kavanaugh, et al.
Clinical and Experimental Rheumatology|October 17, 2013
Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologistTheodore Pincus, Juergen Braun, Arthur Kavanaugh, et al.
The Journal of Rheumatology|December 7, 2005
Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trialsSusan J Lee, Leslie Lenert, Stuart Weisman, et al.
Rheumatology and Therapy|May 20, 2022
Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational studyBrigitte Michelsen, Kristine Thomassen Berget, Arthur Kavanaugh, et al.
Modern Rheumatology|March 19, 2021
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trialsYoshiya Tanaka, Arthur Kavanaugh, Jason Wicklund, et al.
Rheumatology (Oxford, England)|September 24, 2021
Anti-citrullinated protein antibodies in patients with psoriatic arthritisTristan A Boyd, DoQuyen H Huynh, John Temple, et al.
Current Opinion in Allergy and Clinical Immunology|June 11, 2011
Biologic modulators in allergic and autoinflammatory diseasesLori Broderick, Louanne M Tourangeau, Arthur Kavanaugh, et al.
Pageof 39

Showing results (101-110 of 381) with videos related to

Sort By:
Pageof 39
The Journal of Rheumatology|October 15, 2022
Prologue: Evidence Informing the GRAPPA 2021 Treatment Recommendations, by DomainEnrique R Soriano, Arthur Kavanaugh, Laura C Coates
The Journal of Rheumatology|February 16, 2022
Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic ArthritisDeepak R Jadon, Arthur Kavanaugh, Ying Ying Leung
Current Opinion in Rheumatology|February 8, 2006
Recent developments in diet and goutSusan J Lee, Robert A Terkeltaub, Arthur Kavanaugh
Gastroenterology|August 6, 2021
Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease ManagementGerhard Rogler, Abha Singh, Arthur Kavanaugh, et al.
Clinical and Experimental Rheumatology|October 17, 2013
Possible discontinuation of therapies in inflammatory rheumatic diseases - as with initiation of therapies, a shared decision between patient and rheumatologistTheodore Pincus, Juergen Braun, Arthur Kavanaugh, et al.
The Journal of Rheumatology|December 7, 2005
Factors affecting rheumatoid arthritis patients' decisions to participate in clinical trialsSusan J Lee, Leslie Lenert, Stuart Weisman, et al.
Rheumatology and Therapy|May 20, 2022
Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational studyBrigitte Michelsen, Kristine Thomassen Berget, Arthur Kavanaugh, et al.
Modern Rheumatology|March 19, 2021
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trialsYoshiya Tanaka, Arthur Kavanaugh, Jason Wicklund, et al.
Rheumatology (Oxford, England)|September 24, 2021
Anti-citrullinated protein antibodies in patients with psoriatic arthritisTristan A Boyd, DoQuyen H Huynh, John Temple, et al.
Current Opinion in Allergy and Clinical Immunology|June 11, 2011
Biologic modulators in allergic and autoinflammatory diseasesLori Broderick, Louanne M Tourangeau, Arthur Kavanaugh, et al.
Pageof 39